http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021207387-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a62ff965ac7442a846166a0bc9ed23f5
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-542
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-14
filingDate 2021-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbe42385a8fe94bdb8c805f275c4aa36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ccd6ca2edb81e6154ef7d2fe0f723c1
publicationDate 2021-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2021207387-A1
titleOfInvention Use of bromodomain inhibitors for treatment of huntington's disease
abstract The present disclosure relates to the use of BRD9 inhibitors to treat Huntington's Disease.
priorityDate 2020-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019023149-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017223452-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020041308-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID432858220
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID118796358
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID117072549
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID412835206

Total number of triples: 40.